The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy

Overview of attention for article published in Frontiers in Medicine, December 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter: 2 X users

Readers on

mendeley: 15 Mendeley

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 1,957 followers.

RT @larrywabrams: @BlackmanRolondo @Transplant_Doc @MDAndersonNews @lab_rezvani @may_daher @NatureMedicine @HindRafei $GMDA Omisirge vs CAR…

Reply Repost Favourite

@BlackmanRolondo @Transplant_Doc @MDAndersonNews @lab_rezvani @may_daher @NatureMedicine @HindRafei $GMDA Omisirge vs CAR-NK or CAR-T is not an either or decision, but different lines of treatment. See this article recommending Allo-SCT when B-cell maligna

Reply Repost Favourite

@BlackmanRolondo @Transplant_Doc @MDAndersonNews @lab_rezvani @may_daher @NatureMedicine @HindRafei Not an either or decision, but different lines of treatment. See this article recommending Allo-SCT when DLBCL patients R/R after CAR-T https://t.co/i4XKTvZ

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.